Trial Profile

A phase I/IIa dose escalation study of CHR-3996 in combination with tosedostat in subjects with relapsed refractory multiple myeloma.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nanatinostat/valganciclovir combination therapy (Primary) ; Tosedostat
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms MUK-three

Most Recent Events

06 Dec 2016 Results (n=20) assessing recommended dose in dose escalation phase of the study was presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
21 Nov 2016 According to a CTI BioPharma media release, data from this trial will be presented at the upcoming 58th American Society of Hematology (ASH) Annual Meeting.
10 May 2016 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com